Platinum compounds as treatment for cancers, and related methods, kits, and compositions
The present invention is a platinum(II) compound comprising a beta-diketonate ligand represented by the following general formula: Or general formula: wherein R 1 and R 2 are independently selected from the group consisting of alkyl optionally substituted, heteroalkyl optionally substituted, and aryl optionally substituted; R 3 and R 4 are independently selected from the group consisting of ammonia, an optionally substituted heterocycle including at least one nitrogen, and an optionally substituted amine, or R 3 and R 4 can be joined together to form a bidentate ligand Z and Y are independently selected from the group consisting of O and S, provided at least one of Z and Y is S; and X— is a counterion. These compounds are useful in the treatment of cancer.
1. A compound having the structure:
wherein X − is a counterion.
2. A compound having the structure:
wherein:
R 1 and R 2 are independently selected from the group consisting of alkyl optionally substituted, heteroalkyl optionally substituted, and aryl optionally substituted, provided at least one of R 1 or R 2 is not alkyl or haloalkyl;
R 3 and R 4 are independently selected from the group consisting of ammonia, an optionally substituted heterocycle including at least one nitrogen, and an optionally substituted amine, or R 3 and R 4 can be joined together to form a bidentate ligand;
and
X − is a counterion.
3. A compound having the structure:
wherein:
R 1 and R 2 are independently selected from the group consisting of alkyl optionally substituted, heteroalkyl optionally substituted, and aryl optionally substituted, provided at least one of R 1 or R 2 is aryl optionally substituted;
R 3 and R 4 are independently selected from the group consisting of ammonia, an optionally substituted heterocycle including at least one nitrogen, and an optionally substituted amine, or R 3 and R 4 can be joined together to form a bidentate ligand;
and
X − is a counterion.
4. A compound having the structure:
wherein:
R 1 and R 2 are independently selected from the group consisting of alkyl optionally substituted, heteroalkyl optionally substituted, and aryl optionally substituted; and
R 3 and R 4 are independently selected from the group consisting of ammonia an optionally substituted heterocycle including at least one nitrogen, and an optionally substituted amine;
X − is a counterion.
5. A compound having the structure:
wherein:
R 1 and R 2 are independently selected from the group consisting of alkyl optionally substituted, heteroalkyl optionally substituted, and aryl optionally substituted;
R 3 and R 4 are independently selected from the group consisting of ammonia, an optionally substituted heterocycle including at least one nitrogen, and an optionally substituted amine, or R 3 and R 4 can be joined together to form a bidentate ligand;
Z and Y are independently selected from the group consisting of O and S, provided at least one of Z and Y is S; and
X − is a counterion.
6. The compound of claim 2 , wherein at least one of R 1 or R 2 is not alkyl or haloalkyl.
7. The compound of claim 2 , wherein at least one of R 3 and R 4 is NH 3 .
8. The compound of claim 2 , wherein each of R 3 and R 4 is NH 3 .
9. The compound of claim 2 , wherein R 3 and R 4 are independently selected from the group consisting of ammonia and an optionally substituted amine, and are not joined together to form a bidentate ligand.
10. The compound of claim 2 , wherein at least one of R 1 or R 2 is aryl optionally substituted.
11. The compound of claim 2 , wherein at least one of R 1 or R 2 is not methyl or —CF 3 .
12. The compound of claim 2 , wherein at least one of R 1 is —CH 3 or —CF 3 and R 2 is aryl, optionally substituted.
13. The compound of claim 2 , wherein each of R 1 and R 2 is aryl, optionally substituted.
14. The compound of claim 5 , wherein Z is O and Y is S.
15. The compound of claim 5 , wherein Z is S and Y is O.
16. The compound of claim 5 , wherein each of Z and Y is S.
17. A pharmaceutical composition, comprising:
a compound as in claim 5 ; and
one or more pharmaceutically acceptable carriers, additives, and/or diluents.